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Although canonical Notch signaling regulates
multiple hematopoietic lineage decisions including
T cell and marginal zone B cell fate specification,
the downstream molecular mediators of Notch func-
tion are largely unknown. We showed here that
conditional inactivation ofHes1, a well-characterized
Notch target gene, in adult murine bonemarrow (BM)
cells severely impaired T cell development without
affecting other Notch-dependent hematopoietic line-
ages such as marginal zone B cells. Competitive
mixed BM chimeras, intrathymic transfer experi-
ments, and in vitro culture of BM progenitors on
Delta-like-expressing stromal cells further demon-
strated that Hes1 is required for T cell lineage
commitment, but dispensable for Notch-dependent
thymocyte maturation through and beyond the beta
selection checkpoint. Furthermore, our data strongly
suggest that Hes1 is essential for the development
and maintenance of Notch-induced T cell acute
lymphoblastic leukemia. Collectively, our studies
identify Hes1 as a critical but context-dependent
mediator of canonical Notch signaling in the hemato-
poietic system.
INTRODUCTION
The Notch signaling cascade is evolutionarily conserved and
regulates many aspects of cell fate decisions and tissue homeo-
stasis in several adult organ systems (Artavanis-Tsakonas et al.,
1999). Vertebrates possess four Notch receptors that are bound
by five different transmembrane ligands of either the Jagged or
the Delta-like family. Notch signaling is initiated by receptor-
ligand interaction between two neighboring cells leading to
successive proteolytic cleavages, which result in liberation of
the intracellular domain of the receptors (NICD). The NICD then
translocates to the nucleus and heterodimerizes with the tran-
scription factor CSL (also known as RBP-J), thereby recruitingIother coactivators, in order to form a functional transactivation
complex that drives gene expression (Bray, 2006).
In the hematopoietic system of adult mice, Notch function is
critical for the development of splenic marginal zone (MZ) B cells
as well as for intrathymic T cell lineage specification and devel-
opment. Moreover, Notch is an important modulator of T cell-
mediated immune responses, and aberrant Notch signaling is
deeply implicated in the pathogenesis of T cell acute lympho-
blastic leukemia (T-ALL) (reviewed in Radtke et al., 2010).
Although these are well-documented functions of Notch
signaling, it is less clear how and through which target genes
and signaling pathways Notch exerts these pleiotropic functions.
The Hes family of genes is the mammalian counterpart of the
Enhancer-of-split type of genes in Drosophila. It represents the
most extensively studied and best-understood Notch target
genes. The mouse genome contains seven Hes family genes,
all of which encode basic helix-loop-helix (bHLH) transcription
factors, which mainly function as repressors. However, only
Hes1, Hes5, andHes7 appear to be inducible by Notch signaling
(Fischer and Gessler, 2007).
In the hematopoietic system, the expression of both Hes1 and
Hes5 has been shown in several blood lineages including
T cells, B cells, and stem cells (Maillard et al., 2008; Saito
et al., 2003; Yu et al., 2006), making them likely candidates for
transmitting Notch functions. Several Hes1 gain-of-function
experiments suggest a potential role of Hes1 in hematopoietic
stem cell (HSC) maintenance (Kunisato et al., 2003; Yu et al.,
2006). Furthermore, most Hes1/ embryos lack a thymus or
develop only a rudimentary thymic structure. In addition,
Hes1-deficient fetal liver (FL) progenitor cells are unable to
undergo T cell differentiation when transplanted into Rag1/
mice (Tomita et al., 1999). These results suggest that Hes1
could be an important mediator of Notch function during T cell
development. In the context of Notch-induced T-ALL, expres-
sion analysis of retrovirally transduced murine bone marrow
(BM) cells expressing NICD revealed strong upregulation of
the Hes1 gene (Kawamata et al., 2002). However, neither
Hes1 nor Hes5 were sufficient for inducing T-ALL when they
are overexpressed in murine BM progenitors. Gene expression
profiling of multiple patient-derived T-ALL cell lines confirmed
HES1 as being one of the major NOTCH1 target genes in
humans (Palomero et al., 2006; Weng et al., 2006), raising themmunity 33, 671–684, November 24, 2010 ª2010 Elsevier Inc. 671
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genic program activated by Notch.
These data show that Hes1 can influence hematopoiesis, lym-
phopoiesis, and possibly Notch-induced leukemia. However, the
presumed critical role of Hes1 as amediator of Notch dependent
and/or independent signaling has not been tested directly under
physiological conditions or in Notch-induced T-ALL models.
Given that Hes1 gene targeted mice die during embryogenesis
(Ishibashi et al., 1995), an inducible gene targeting approach
was used. Here, we showed that under physiological conditions
Hes1 was a major component of the Notch-induced genetic
program necessary for efficient T cell lineage commitment. In
contrast, subsequent stages of thymocyte development, as
well as Notch-mediated specification of MZ B cell development,
were not perturbed in the absence of Hes1. Moreover, in the
context of Notch-induced T-ALL, we demonstrated that Hes1
plays an important role for both the development and the main-
tenance of murine T-ALL. Thus, these findings identify Hes1 as
a critical but context-dependent genetic modulator of canonical
Notch signaling in the hematopoietic system under physiological
and pathological conditions.
RESULTS
Hes1 Is Dispensable for HSC Maintenance
and Self-Renewal
Hes1 could play an important role for HSCmaintenance because
human umbilical cord blood stem cells express high amounts of
Hes1 mRNA (Yu et al., 2006), and forced Hes1 expression in
human or murine HSCs results in increased numbers of quies-
cent HSCs or side populations that correlate with increased
preservation of long term engraftment (Kunisato et al., 2003;
Yu et al., 2006). Because canonical Notch signaling is not essen-
tial for HSC maintenance and/or self-renewal (Maillard et al.,
2008), Hes1 was not expected to be important for HSCs as
a Notch target gene. Nevertheless, Hes1 expression can also
be regulated independently of Notch signaling (Ferna´ndez-Ma-
jada et al., 2007; Issack and Ziff, 1998), and it is therefore
possible that Hes1 might exert important Notch-independent
functions in HSCs. To directly address the role of Hes1 in adult
HSCs and hematopoiesis, we generated a conditional mouse
model by using the Cre-loxP system. Transgenic mice express-
ing the Cre recombinase under the control of the IFN-inducible
Mx promoter (Ku¨hn et al., 1995) were crossed to mice in which
exons 2–4 of the Hes1 gene are flanked by loxP sequences
(Hes1lox/lox). Hes1lox/lox (control) and Hes1lox/loxMxCre mice
were treated with the IFN-a inducer pI-pC five times at 2 day
intervals (Figure 1A). Southern blot analysis 6 weeks after induc-
tion ofHes1DMxCre BM cells revealed a nearly 100% deletion effi-
ciency (Figure 1B). Moreover, qRT-PCR analysis of sorted HSC
for Hes5 suggests that the absence of a noticeable phenotype
is not the consequence of compensatory upregulation of Hes5
in the absence of Hes1 (Figure S1C).
Analysis of control and Hes1DMxCre mice 8–10 weeks after
Hes1 inactivation revealed no effect on the relative frequency
or the absolute numbers of the HSC compartment including
LT-HSC, ST-HSCs, and multipotent progenitors (MPPs)
(Figures 1C and 1D), suggesting that Hes1 is dispensable for
steady state homeostasis of HSCs. Similarly, no alterations of672 Immunity 33, 671–684, November 24, 2010 ª2010 Elsevier Inc.myeloid, erythroid, and B cell lineages were detected (Figures
S1A and S1B). Moreover, the relative contribution, as well as
the proliferative capacity of Hes1-deficient BM cells and
HSCs, was equal to control cells when tested in competitive
BM chimeras (Figure 1E, left panel, and Figure S1D). Efficient
deletion of Hes1 alleles was confirmed by PCR of both input
and output BM cells (Figure 1F). Serial transplantations were
performed to rigorously test the repopulation and engraftment
capabilities of Hes1-deficient HSCs of primary mixed chimeras.
Four months after transplantation secondary recipients showed
that the relative contribution of CD45.2+ cells in the BM was
nearly identical between control and Hes1DMxCre mixed BM
chimeras (Figure 1E, right panel). These results were confirmed
in an in vivo challenge system in which control or Hes1DMxCre
mice were exposed to repeated doses of the antimetabolite 5-
fluorouracil (5-FU). The percentage of surviving Hes1DMxCre
mice was similar to control mice (Figure S1E), indicating that
Hes1DMxCre HSCs can reenter the cell cycle to repopulate all
hematopoietic lineages. These results demonstrate that loss
of Hes1 function does not compromise HSC self-renewal in
steady state homeostasis as well as under stringent challenge
situations. Although the data are consistent with the fact that
canonical Notch signaling is not required for HSC self-renewal
and/or maintenance (Maillard et al., 2008), it is still conceivable
that noncanonical Notch signaling might influence these
processes.
Hes1 Is Dispensable for MZ B Cell Development
Specification of the MZ versus follicular (Fo) B cell fate in the
spleen is mediated via the nonredundant interaction between
Notch2 on MZ B cell precursors and Delta-like1 (DL1) on splenic
endothelial cells (Hozumi et al., 2004; Saito et al., 2003; Tan et al.,
2009; Tanigaki et al., 2002). We tested the hypothesis that the
development ofMZB cells could be dependent on Hes1 function
by performing FACS analysis of splenocytes derived from
control and Hes1DMxCre BM chimeras for the presence of Fo
and MZ B cells 12 weeks after BM transplantation. This analysis
revealed no differences in the relative frequency and absolute
numbers of CD45.2+ MZ or Fo B cells in the absence of Hes1
(Figures 2A and 2B). Even when tested in competitive BM
chimeras, Hes1-deficient progenitors were able to generate
MZ and Fo B cells as efficiently as control progenitors (Figures
2C and 2D), indicating that Hes1 is dispensable for DL1-
Notch2-mediated MZ B cell fate specification.
Hes1 Is Required at an Early Stage of T Cell
Development
Canonical Notch signaling mediated by the Notch1-Delta-like 4
(DL4) receptor ligand pair is essential for thymic T cell fate spec-
ification (Hozumi et al., 2008; Koch et al., 2008). Conditional defi-
ciency ofNotch1 or DL4 leads to an accumulation of immature B
cells and abrogation of the T cell fate in the thymus. In addition,
developing thymocytes require continuous Notch signaling to
successfully transition through the b-selection checkpoint
(Ciofani et al., 2004).
To test whether Hes1 is involved in mediating Notch1-induced
T cell lineage specification or maturation, we analyzed thymo-
cytes of control and Hes1DMxCre BM chimeras. Although, FACS
analysis of CD4 and CD8 expression revealed no substantial
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Figure 1. Conditional Targeting Strategy of the Hes1 Gene and Repopulation Potential of Hes1-Deficient HSCs
(A) Schematic representation of the modified genomicHes1 locus is shown together with corresponding protein domains. LoxP sites are indicated by black trian-
gles.Hes1lox/loxmice were crossed toMxCre transgenic mice so thatHes1lox/loxMxCremice could be obtained. Respective band sizes detected by Southern blot
analysis of PstI digested genomic DNA are indicated. The asterisk indicated the position of the probe enabling fragment detection. F1, R1, and R2 show the posi-
tion of primers used for Hes1 detection.
(B) Southern blot analysis of genomic DNA from control (Hes1lox/lox; lanes 1 and 2) and Hes1-deficient (Hes1DMxCre; lanes 3–5) total BM cells after pI-pC treatment.
The 1.9 kb fragment corresponds to the floxed Hes1 allele and the 1.4kb fragment to the recombined locus.
(C and D) Representative FACS analysis of KLS HSCs defined by CD117 and Sca1 after gating on Lin BM cells derived from Ctrl and Hes1DMxCre littermates.
(D) Quantification of total KLS HSCs, LT-HSCs, ST-HSCs, and MPPs gated on Lin BM cells derived from Ctrl (white bars, n = 8) and Hes1DMxCre (black bars,
n = 10) littermates 8 weeks after pI-pC treatment. Error bars represent the mean standard deviation (±SD).
(E and F) Long-term chimerism under competitive conditions: WT CD45.1+ BM cells were mixed at a 1:3 ratio with Ctrl or Hes1DMxCre BM cells transplanted and
analyzed.
(E) Percentage of Ctrl and Hes1DMxCre CD45.2+ cells in BM of recipients at 12 weeks (n = 8 per group). Percentage of Ctrl (n = 4) and Hes1DMxCre (n = 6) CD45.2+
cells in BM of secondary recipients at 16 weeks.
(F) Hes1 deletion PCR on total BM cells prior to (input) and 12 weeks (output) after 1 transplantation of individual mice. Band sizes indicate PCR products of
Hes1wt, control (Hes1lox), and the Hes1DMxCre deletion fragment (DHes1). Data from (B)–(E) are representative of two independent experiments. See Figure S1.
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DN (CD4CD8), DP (CD4+CD8+), CD4+ and CD8+SP thymocyte
subpopulations (Figure 3A), the total cellularity of the thymuswas
reduced by more than 80% compared to the control (Figure 3B).
Hes1 deletion was confirmed by PCR on sorted DP thymocytes
derived from control and Hes1DMxCre chimeras (Figure 3C),
whereas compensatory upregulation of Hes5 in DN thymocytesIwas excluded as a possible explanation for the phenotype
(Figure S1C).
Further analysis of the DN compartment of control and
Hes1DMxCre chimeras revealed that the absolute cell numbers
of the corresponding DN thymocyte subsets were reduced to
1/10 for DN1, 1/84 for DN2, 1/22 for DN3, and to 1/5 for DN4
(Figures S2A and S2B). icTCRb staining on DN3 and DN4 cellsmmunity 33, 671–684, November 24, 2010 ª2010 Elsevier Inc. 673
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Figure 2. Unperturbed MZ B Cell Develop-
ment in the Absence of Hes1
(A and B) BM chimeras of Ctrl and Hes1DMxCre
were analyzed at 12 weeks by FACS.
(A) Representative contour plots of splenocytes
from Ctrl and Hes1DMxCre chimeras assessing the
MZ B cells defined by CD21 and CD23 (gated on
CD45.2+ B220+ cells) are shown.
(B) Bar graph showing the absolute number (±SD)
of total splenocytes, total B cells and MZ B cells
from Ctrl (white bars) and Hes1DMxCre (black
bars) chimeras.
(C and D) Long-term chimeras under competitive
conditions analyzed at 12 weeks as described in
Figure 1.
(C) Representative FACS analysis of the MZ B cell
population analyzed as described in (A).
(D) Bar graph showing the absolute number (±SD)
of total B cells and MZ B cells gated on CD45.2+
cells in spleens of Ctrl (white bars) and Hes1DMxCre
(black bars) in 1 mixed BM chimeras (n = 8 per
group). Data are representative of two indepen-
dent experiments.
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Hes1DMxCre chimeras are true immature thymocytes (Fig-
ure S2C). In addition, thymic B cells of both groups were pheno-
typically similar and did not accumulate as a consequence of
Hes1 inactivation (Figure S2E), which is unlike the situation found
in Notch1-deficient mice (Koch et al., 2008; Radtke et al., 1999).
Furthermore, we confirmed that the thymic hypoplasia of Hes1
mutant mice was due to neither increased cell death nor
reduced proliferative capacity (data not shown). Taken together,
these results suggest that once Hes1-deficient progenitors are
committed to the T cell lineage, subsequent maturation and
transition through b selection occurs normally. We directly
confirmed this interpretation by analyzing Hes1lox/lox mice that
were crossed to Lck- (Figures S2F and S2G) and Cd4-Cre
(data not shown) transgenic mice, which inactivate floxed
target genes at DN3 and DN4 thymocyte stages, respectively
(Wolfer et al., 2002). Analysis of thymocyte subsets from
Hes1DLckCre and Hes1DCd4Cre mice did not reveal any noticeable
phenotypes and absolute numbers of all subsets were normal
(Figures S2F and S2G and data not shown). Consistent with
Hes1 being important at earlier stages of T cell development,
gd T cells of Hes1DMxCre BM chimeras were reduced both in
frequency (data not shown) and absolute numbers to a similar
extent (1/7) as ab T cells (compare Figure S2D to Figure 3B).
The disadvantage of Hes1-deficient progenitors to efficiently
give rise to T cells was further investigated in a competitive trans-
plant setting. Although CD45.2+ control cells contributed on
average 90% to thymic chimerism, the contribution of Hes1-defi-
cient BM cells varied between 1%–5%, revealing a dramatic
failure in their ability to contribute to thymus cellularity in
a competitive situation (Figure 3D). Analysis of the CD4 and
CD8 expression profile revealed that the Hes1-deficient cells
within the thymus of themixed BM chimeras can indeed develop674 Immunity 33, 671–684, November 24, 2010 ª2010 Elsevier Inc.into DP, CD4, and CD8 SP thymocytes (Figure 3E). However, in
absolute numbers their contribution to DP thymocytes was
reduced 400-fold (Figure 3F). Thus, Hes1 is required at early
stages of T cell development but is dispensable for Notch-
dependent thymocyte maturation through and beyond the beta
selection checkpoint.
Hes1 Deficiency Results in Impaired T Cell Lineage
Commitment
The inability of Hes1DMxCre BM progenitors to repopulate the
thymus in a competitive setting could either be the result of
impaired homing of BM progenitors to the thymus or an impaired
ability of thymus-seeding cells to efficiently develop into T cells.
We addressed this question by a series of intrathymic (IT)
transfer experiments. We IT-injected Lin BM progenitors from
control and Hes1DMxCre mice into individual lobes of congenic
hosts in order to bypass the need for migration. IT-transferred
Hes1-deficient BMprogenitors developed into T cells (Figure 4A),
although with markedly slower kinetics compared to control
cells (Figures 4A and 4B). FACS analysis 21 days after IT transfer
revealed no significant differences in the percentage of
control and Hes1DMxCre-derived DN, DP, CD4+, and CD8+ SP
thymocyte subpopulations (Figure 4A). Successful inactivation
of Hes1 was confirmed on Lin input BM cells and on
sorted CD45.2+ DP thymocytes derived from control or
Hes1DMxCre IT-injected progenitors (Figure 4C). However, anal-
ysis of the DN thymic compartment showed that the frequency
of Hes1DMxCre cells within the DN1 gate was clearly increased
in relative numbers compared to the corresponding control pop-
ulation (Figure 4A). The antibody lineage cocktail and gating
strategy allowed us to exclude the possibility that these cells
are aberrant myeloid, B, NK, or mast cells, suggesting that these
cells are indeed DN1 (CD117+CD44+CD25B220) thymocytes
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Figure 3. Hes1 Deficiency Results in Thymic Hypoplasia
(A–C) BM chimeras of Ctrl and Hes1DMxCre were analyzed at 12 wks by FACS (n = 8 per group).
(A) Representative analysis of thymocytes from Ctrl and Hes1DMxCre chimeras. Total CD45.2+ thymocytes were stained with aCD4 and aCD8 mAbs.
(B) Total cell numbers of donor thymocytes and indicated subsets (DP, CD4 SP, and CD8 SP) are shown as bar diagrams (Ctrl [white bars] andHes1DMxCre [black
bars]; ***p < 0.0001). Error bars represent the mean standard deviation (±SD).
(C) PCR analysis ofHes1 from sorted donor DP cells of Ctrl (lane 1 and 2) andHes1DMxCre (lane 3 and 4) chimeras. The asterisk denotes band sizes corresponding
to uninduced Hes1lox/+ thymocytes. The top band size indicates the Hes1DMxCre deletion fragment.
(D–F) Long-term competitive chimeras were analyzed at 12 weeks (n = 8 per group).
(D) Percentage of Ctrl or Hes1DMxCre CD45.2+ cells in thymocytes of 1 recipients (***p < 0.0001).
(E) Representative FACS analysis of thymocytes derived from Ctrl and Hes1DMxCre chimeras. Total CD45.2+ donor-derived thymocytes were stained with aCD4
and aCD8 mAbs.
(F) Quantification of total donor-derived CD45.2+ DP (CD4+CD8+) thymocytes comparing Ctrl (white bars) and Hes1DMxCre (black bars) competitive BM chimeras
(***p < 0.0001). Data from (A) and (B) represent three and data from (D)–(F) represent two independent experiments. See Figure S2. Error bars represent the mean
standard deviation (±SD).
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Hes1 Is Critical for T Cell Development and T-ALLderived fromHes1-deficient progenitors. This relative increase in
the DN1 population was more evident at early time points (day
16), suggesting that progenitors in the absence of Hes1 needIlonger to integrate a Notch1-mediated genetic program that
would allow them to subsequently progress to the next thymo-
cyte stage. To further confirm this cell-intrinsic defect ofmmunity 33, 671–684, November 24, 2010 ª2010 Elsevier Inc. 675
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Figure 4. T Cell Fate Specification Is Impaired in Hes1-Deficient Progenitors
(A–C) Ctrl or Hes1DMxCre Lin-CD45.2+ BM cells were injected IT into congenic recipients and analyzed by FACS.
(A) FACS analysis of thymocytes of individual lobes of recipients injected either with Ctrl or Hes1DMxCre progenitors assessing T cell development at day 16 or 21.
Total CD45.2+ thymocytes were stained with aCD4 and aCD8 mAbs (top panel), and CD4CD8Lin thymocytes were stained with aCD25 and aCD44 mAbs
(gated on CD44 and CD117; bottom panel).
(B) Time kinetics of reconstitution by Ctrl or Hes1DMxCre LinCD45.2+ BM cells (n = 6 per time point ± SD).
(C)Hes1 deletion PCR of input Ctrl (lane 1) andHes1DMxCre (lane 2) LinCD45.2+ BM and of sorted DP at day 21 fromCtrl (lane 3 and 4) andHes1DMxCre (lane 5 and
6) reconstituted thymi. Lanes 1–6 represent samples of individual lobes. The asterisk denotes band sizes corresponding to uninduced Hes1lox/+DP cells. The top
band size indicates the Hes1DMxCre deletion band.
(D) Ctrl or Hes1DMxCre LinCD45.2+ BM and LinCD45.1+CD45.2+ double congenic (competitor) BM cells were mixed at a 1:1 ratio and injected IT into congenic
recipients. At day 16, thymocytes from individual lobes were assessed for reconstitution by either Ctrl or Hes1DMxCre as compared to competitor cell progeny.
Contour plots represent an analysis of thymocytes stained with aCD45.1 and aCD45.2 mAbs (left panel). Competitor and either Ctrl or Hes1DMxCre (CD45.2+)
thymocytes were stained with aCD4 and aCD8 mAbs gated on either double or single congenic thymocytes.
(E and F) Bar graphs represent the absolute numbers of immature B220+ (**p < 0.05) and of DP T (***p < 0.0001) cells detected in individual lobes gated onCD45.2+
cells of Ctrl (white bars) versus Hes1DMxCre (black bars). Data from (A)–(C) represent three experiments, and data from (D)–(F) represent two independent exper-
iments. Error bars represent the mean standard deviation (±SD).
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were performed. Congenic hosts were injected with either
CD45.2+ Hes1DMxCre or control CD45.2+ Lin BM cells, each
mixed at a 1:1 ratio with CD45.1+CD45.2+ WT BM cells. Sixteen
days after transfer the control cells contributed similarly as
CD45.1+CD45.2+ WT cells to the thymic cellularity, whereas
the contribution of CD45.2+ Hes1DMxCre BM cells was strongly
impaired. The few cells that contributed to overall thymic cellu-
larity were able to differentiate into DP, CD4+, and CD8+SP
thymocytes, although the majority of cells fell into the DN
compartment. Further analysis of the Hes1DMxCre DN compart-
ment revealed that the majority of these cells were immature B
cells (Figure 4E and data not shown). In absolute numbers,
immature B cells were on average increased 10-fold, whereas
the numbers of DP thymocytes were reduced to 1/60 (Figures
4E and 4F). Thus, in competitive IT transfer experiments, the
majority of Hes1DMxCre BM progenitors can presumably not effi-
ciently compete with WT cells for access to the thymic niche.
Only a small subset of Hes1-deficient progenitors receive suffi-
cient Notch1 signaling to commit to the T cell lineage and to
develop into T cells, whereas the majority do not receive the
necessary level of the Notch1-induced genetic program to
successfully induce T cell commitment and therefore develop
by default into immature B cells. If this interpretation is correct,
then the threshold for Hes1-deficient progenitors to develop
into B cells as a consequence of receiving a weak Notch1 signal
should be lower compared to WT progenitors. We tested this
hypothesis in the OP9 culture system. Previously, we estab-
lished a hierarchy of Notch-DL interactions in which Notch1-
DL4 exhibits greater binding avidity than Notch1-DL1 (Bessey-
rias et al., 2007). Sorted control and Hes1DMxCre HSC popula-
tions were cultured on either DL1- or DL4-OP9 cells and
analyzed between day 17 and 21 after seeding. Control HSCs
developed efficiently within 21 days into DP thymocytes with
both OP9 culture systems. In contrast, Hes1DMxCre HSCs devel-
oped into DP thymocytes only when cultured on DL4 but not on
DL1 expressing OP9 cells (Figures 5A and 5C). Analysis of imma-
ture thymocytes showed that Hes1DMxCre but not control HSCs
exhibit a developmental block within the DN compartment
resembling the most immature DN1 (CD44+CD25) thymocyte
stage when cultured on OP9-DL1 but not if cultured on OP9-
DL4 cells (Figure 5B). Further analysis for B cell-specific markers
such as CD19 and IgM showed that the vast majority of these
Hes1DMxCre cells derived from the OP9-DL1 culture are immature
B cells (Figure 5B). We observed a 100-fold increase in absolute
numbers of immature B cells generated by Hes1-deficient HSCs
compared to WT cells with the OP9-DL1 system (Figure 5D).
Thus, these experiments demonstrate that in the absence of
Hes1 HSCs are unable to adopt the T cell lineage on DL1 ex-
pressing OP9 cells, which in this context represent a suboptimal
ligand for Notch1. Taken together, these data strongly suggest
that Hes1 is an essential component of the Notch1-induced
genetic program and that it is necessary for efficient T cell
lineage commitment.
Role of Hes1 in Induction of T-ALL
More than 50% of T-ALL patients carry activating Notch1muta-
tions (Weng et al., 2004). Gene expression analysis of patient-
derived T-ALL cell lines shows that Hes1 is strongly upregulatedIas a consequence of increased Notch1 signaling activity (Palo-
mero et al., 2006; Weng et al., 2006). To directly investigate
whether Hes1 is required for the transformation of hematopoietic
progenitors in Notch1-induced T-ALL, we crossed Hes1lox/lox
MxCre mice to RosaNIClox/+ mice (Murtaugh et al., 2003). The
RosaNIClox/+ model is a gene-targeted mouse in which NICD1 is
preceded by a floxed STOP cassette, followed by an IRES-
eGFP cDNA, and knocked into the ubiquitously expressed
Rosa locus (Murtaugh et al., 2003; Soriano, 1999). pI-pC treat-
ment of RosaNIClox/+Hes1lox/loxMxCremice leads to the simulta-
neous expression of NICD1 and deletion of the floxed Hes1
alleles. To avoid the systemic effects of MxCre induced NICD1
expression,weperformedall experiments in aBM transplantation
setting. BM cells derived from RosaNIClox/+MxCre, RosaNIClox/+
Hes1lox/loxMxCre or control RosaNIClox/+Hes1lox/lox mice were
transplanted into congenic recipients. Six weeks after transplan-
tation chimeras were injected with pI-pC, monitoring the life span
of the different chimeric mice revealed a median survival time of
26 days for RosaNICD/+MxCre and 250 days for RosaNICD/+
Hes1DMxCre chimeras. Control chimeras survived with 100%
penetrance for the duration of the experiment (Figure 6A). Hes1
deficiency resulted on average in a 10-fold increase in survival
of RosaNICD/+Hes1DMxCre compared to RosaNICD/+MxCre
chimeras, suggesting that Hes1 plays an important role in the
induction of NICD1-induced T-ALL. Three weeks after pI-pC
injection, the BMofRosaNICD/+MxCre chimeraswas almost exclu-
sively composedofCD45.2+eGFP+DP leukemiccells (Figure6C).
Similarly a largepopulationofDP leukemic cellswasdetectable in
the spleens of thesemice (Figure 6C), indicating extensive infiltra-
tion of peripheral organs by leukemic DP cells derived from the
BM. The spleens revealed severe splenomegaly harboring on
average 250 3 106 DP leukemic cells (Figure 6D). In contrast, at
3weeks theBMcompartmentofRosaNICD/+Hes1DMxCrechimeric
mice contained on average only 40% of CD45.2+eGFP+DP
leukemic cells, which increased to 60% by 12 weeks and
disappeared by 24 weeks (Figure 6C). In the spleens of
RosaNICD/+MxCreHes1DMxCre mice, a maximum of 2% DP
leukemic cells were detectable at the 12 week time point (Fig-
ure 6C), which corresponds to a 1/1000 fraction of leukemic cells
compared to RosaNICD/+MxCre chimeras (Figure 6D). Moreover,
the WBC counts of RosaNICD/+Hes1DMxCre chimeras were com-
parable to those of control animals, whereas RosaNICD/+MxCre
chimeras exhibited clearly increased WBC counts (Figure S3A).
The correct recombination of the floxed Hes1 alleles in the corre-
sponding BM chimeras was verified by PCR on CD45.2+ DP cells
(Figure 6B). As expected, Hes1 mRNA expression was no longer
detectable in DP cells derived from RosaNICD/+Hes1DMxCre
chimeras, whereas it was increased 200-fold inRosaNIC D/+MxCre
chimeras compared to WT DP thymocytes. Hes5 mRNA expres-
sion was increased 4-fold in RosaNIC D/+MxCre chimeras but was
not further upregulated as a consequence ofHes1 gene inactiva-
tion in the RosaNIC mouse model (Figure S3B). Interestingly, the
NICD1-induced repression of B cell development in the BM
(Pui et al., 1999) persisted in RosaNICD/+Hes1DMxCre chimeric
mice (Figure S3C), indicating that Hes1 deficiency is not sufficient
to rescue the NICD1 induced suppression of B cell development.
Loss of Hes1 in Drosophila and human cell culture experi-
ments was linked to increased activity of the Akt pathway (Palo-
mero et al., 2007). We tested this possibility in our murine T-ALLmmunity 33, 671–684, November 24, 2010 ª2010 Elsevier Inc. 677
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Figure 5. Hes1-Deficient KLS Develop into B Cells on OP9-DL1 and T Cells on OP9-DL4 Cells
(A) KLS from Ctrl and Hes1DMxCre total BM cells were cultured on either OP9-DL1 or OP9-DL4 for 17–21 days. FACS analyses of Lin+ cells versus FSC and CD4
versus CD8 of Ctrl and Hes1DMxCre KLS cultured on OP9-DL1 or OP9-DL4 are shown.
(B) Cells (Ctrl andHes1DMxCre) were gated on LinDN thymocytes and analyzed for CD44 and CD25, and for CD19 versus IgM expression gated on CD44+CD25
cells.
(C) Bar graphs represent the quantification of DP cells.
(D) Bar graphs represent the quantification of immature B cells by gating on Lin-CD44+CD25CD19+IgM cells. Data are representative of three independent
experiments.
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Hes1 Is Critical for T Cell Development and T-ALLmodel. Quantitative RT-PCR for PTEN expression and intracel-
lular staining for phospho-Akt on sorted DP cells from NICD1 ex-
pressing control and Hes1DMxCre BM-derived cells did not show
any significant differences between the two populations tested
(Figures S3D and S3E). Moreover, expression of the Notch
target gene c-Myc was not significantly altered in NICD1 ex-
pressing DP cells lacking Hes1 (Figure S3F). These results678 Immunity 33, 671–684, November 24, 2010 ª2010 Elsevier Inc.suggest that in our model system Hes1 does not importantly
regulate the Akt pathway or c-myc expression. Although the
mechanistic function of Hes1 needs further investigation and
depletion of leukemic precursors as a consequence of Hes1
gene inactivation cannot be formally excluded, our results
strongly suggest that Hes1 is essential for the development of
murine T-ALL.
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Figure 6. Role of Hes1 in the Induction and
Progression of NICD1-Induced T-ALL
Chimeras were set up from RosaNIClox/+Hes1lox/lox
(WT), RosaNIClox/+MxCre, and RosaNIClox/+
Hes1lox/loxMxCre (CD45.2+) BM cells. Reconstitu-
tion was confirmed and chimeras received pI-pC
injections.
(A) Kaplan-Meier curves depict survival of
RosaNIC D/+MxCre (gray line; n = 18), RosaNICD/+
Hes1DMxCre (black line; n = 16), and RosaNIClox/+
Hes1lox/lox (black dashed line; n = 7) chimeras.
The dashed line indicates T50median survival time.
(B) Hes1 deletion efficiency in leukemic DP
donor-derived cells sorted from BM of the indi-
cated groups. Lane 1 shows PCR fragment of
uninduced Hes1lox/+ DP DNA. Lanes 2 and 3
show PCR products of DNA from sorted DP cells
derived from RosaNICD/+MxCre and lanes 4 and 5
depict PCR fragments from sorted DP cells
from RosaNICD/+Hes1DMxCre chimeras. The top
band corresponds to theHes1DMxCre deletion frag-
ment.
(C) FACS analysis of BM (upper panels) and spleen
(lower panels) stained with aCD4 and aCD8mAbs,
gated on donor-derived CD45.2+eGFP+ cells of
RosaNICD/+MxCre chimeras 3 weeks after the last
pI-pC injection and RosaNICD/+Hes1DMxCre
chimeras 3, 12, and 24 weeks after the last pI-pC
injection. WT contour plots correspond to BM
and spleen derived from RosaNIClox/+Hes1lox/lox
chimeras 3 weeks after induction.
(D) Absolute cell numbers of leukemic donor-
derived DP cells present in the BM and spleen of
RosaNICD/+MxCre (white bars; n = 7) and
RosaNICD/+Hes1DMxCre (black bars; n = 7)
chimeras. Statistical significance was calculated
using Student’s t test (*p < 0.01, ***p < 0.0001).
Data from C-D represent two independent experi-
ments. See Figure S3. Error bars represent the
mean standard deviation (±SD).
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For investigating whether Hes1 is also necessary for the mainte-
nance of Notch-induced T-ALL, a well-characterized transplan-
tationmodel was used (Pui et al., 1999). LinBMcells from either
control or Hes1lox/loxMxCremice were isolated and infected with
a bicistronic retroviral vector expressing NICD1 and then with an
eGFP (Migr1-NICD1). Analysis of peripheral blood lymphocytes
(PBLs) 4 weeks after transplantation showed that 20%–30%
of PBLs are derived from eGFP expressing CD45.2+ control or
Hes1lox/loxMxCre donor cells. The vast majority of these donor-
derived cells were DP, which is a hallmark of T-ALL (Figure 7A).
After establishment of T-ALL, both sets of chimeric mice were
treated with pI-pC to inactivate the floxed Hes1 alleles. By this
time, the percentage of CD45.2+eGFP+ control-derived donor
cells within PBLs had increased to 75%. Moreover, the majority
of leukemic NICD1 expressing control-derived cells had
developed into CD8+ cells, which is a phenotypic indication of
disease progression (Figure 7B). In contrast, CD45.2+eGFP+IHes1DMxCre-derived cells contributed on average to only 5% of
PBLs, indicating a loss of leukemic cells as a consequence of
Hes1 inactivation (Figure 7B).
Continuous pI-pC treatment of chimeras having received
Migr1-NICD1-infected BM cells derived from Hes1lox/loxMxCre
mice led to a 2-fold prolonged survival (Figure 7C). Despite
continuous Hes1 inactivation, we were not able to eradicate
the CD45.2+eGFP+ leukemic cells, which maintained the typical
DP phenotype. PCR analysis of total BM cells revealed a hetero-
geneous cell population with some cells carrying the inactivated
Hes1 allele while others maintained the floxed Hes1 alleles
(Figure 7D). To test whether the inability to eradicate the
leukemic cells by inactivating Hes1 is due to a counter selection
for leukemic cells that escaped Cre-mediated inactivation of
Hes1, we serially transplanted BM cells from the primary recipi-
ents into secondary recipients. Three weeks after serial trans-
plantation, 80% of PBLs were derived from CD45.2+ donor cells,
of which more than 90% were positive for eGFP, which ismmunity 33, 671–684, November 24, 2010 ª2010 Elsevier Inc. 679
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Figure 7. Role of Hes1 in T-ALL Maintenance
Hes1lox/lox andHes1lox/loxMxCreCD45.2+ BMcells were in-
fected with Migr1-NICD1-eGFP retrovirus. Transduced
cells were transplanted into congenic recipients. Four
weeks after BM transplantation, recipients received pI-pC.
(A) Percentages of donor leukemic cells (CD45.2+eGFP+)
within peripheral blood lymphocytes (PBLs) of recipients
are shown prior to pI-pC treatment (left panel; Hes1lox/lox,
white bars, Hes1lox/lox MxCre, black bars; n = 5 per group).
FACS analysis of CD4 and CD8 expression on PBLs gated
on CD45.2+eGFP+ is shown.
(B) Percentages of donor leukemic cells (CD45.2+eGFP+)
within PBLs of recipients are indicated 3 days after induc-
tion (left panel; Ctrl, Hes1lox/loxMigr1-NICD1, white bars,
Hes1DMxCre, Hes1DMxCre Migr1-NICD1, black bars; n = 5
per group). FACS analysis of CD4 and CD8 expression
on PBLs gated on CD45.2+eGFP+ is shown.
(C) Kaplan-Meier survival curves of Hes1lox/loxMigr1-
NICD1 (black line; n = 12) and Hes1DMxCreMigr1-NICD
(gray line; n = 6) chimeras after continuous pI-pC treatment
(23 i.p. injections pI-pC per week). Dashed line indicates
T50 median survival time.
(D and E) BM cells from the primary recipients of
Hes1DMxCreMigr1-NICD1 were transplanted into
secondary congenic recipients and PBLs were analyzed.
(D) Hes1 deletion by PCR. Left image (1 transplantation)
shows the PCR products from three individual BM
samples of 1 and the right image (2 transplantation)
depicts the PCR products from three individual PBL
samples (lane 1–3) of 2 recipients. Lower band indicates
the PCR product of Hes1 wild-type (WT), the middle
band resolves the control (Hes1lox/lox) fragment and the
top band indicates the Hes1DMxCre deletion fragment.
(E) FACS analysis of PBLs from 2 recipients of the
Hes1DMxCreMigr1-NICD genotype assessed for the con-
genic markers CD45.1 and CD45.2 and gated on
CD45.2+ cells to show surface expression of CD4 versus
CD8 6 weeks after serial transplantation. See Figure S4.
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cells. Moreover, analysis of CD4 and CD8 surface expression re-
vealed that more than 70% of the cells had progressed to the
more aggressive CD8+ phenotype (Figure 7E). Analysis of Hes1
deletion efficiency revealed that the donor-derived cells were
positive exclusively for the floxedHes1 allele (Figure 7D), demon-
strating that there is a strong counter selection for leukemic cells
having escaped Hes1 gene inactivation. Secondary recipients of
Hes1DMxCre Migr1-NICD1 BM cells exhibited a similar survival
kinetic as primary recipients of control Migr1-NICD1 BM with
a mean survival of 56 days and a maximum life expectancy of
62 days (Figure S4A).
Taken together, these results show that inactivation of Hes1 in
a preexisting population of DP leukemic cells results in the rapid680 Immunity 33, 671–684, November 24, 2010 ª2010 Elsevier Inc.elimination of these cells. Although we cannot
formally exclude that Hes1 inactivation results
in the depletion of leukemic progenitors, our
results strongly suggest that Hes1 is essential
for the maintenance of NICD1-induced T-ALL
in mice.
To investigate whether Hes1 might also be
important for human T-ALL we knocked down
Hes1 in an established patient-derived andNotch-dependent T-ALL cell line (T-ALL1) (Weng et al., 2004)
with shRNA. The knockdown of Hes1 mRNA varied between
50%–70% compared to scrambled shRNAs (Figure S4B).
T-ALL1 cells in which Hes1 was knocked down revealed severe
growth disadvantages accompanied by increased cell death
compared to T-ALL1 cells expressing scrambled shRNAs
(Figures S4C–S4E). These data support an important role of
Hes1 in human T-ALL.
DISCUSSION
The bHLH transcription factor Hes1 is one of the best-accepted
direct Notch target genes. However, which particular Notch-
dependent and possibly -independent functions within the
Immunity
Hes1 Is Critical for T Cell Development and T-ALLhematopoietic system of adult mice are mediated by Hes1 has
not been directly investigated to date. In this study, we
addressed this question by inducibly ablating Hes1 within the
hematopoietic compartment under physiological as well as
pathological conditions.
Hes1 expression is often upregulated by Notch signaling in
different hematopoietic lineages including MZ B cells and imma-
ture thymocytes (Saito et al., 2003; Tan et al., 2009). Neverthe-
less, our results demonstrate that the functional requirement of
Hes1 for these two lymphoid lineages differs. Whereas Hes1 is
dispensable for MZ B cell development, it plays an important
role for T cell development. Thus, our data suggest that the
Notch signaling-dependent specification of the MZ B and
T cell fate depends on the induction of different genetic
programs. Some of the differences in Notch-induced genetic
programs may be related to the differential usage of Notch
signaling components including Notch receptors and ligands.
MZ B cell development is dependent on DL1-mediated Notch2
signaling (Hozumi et al., 2004; Saito et al., 2003), whereas
in vivo T lineage commitment and thymocytematuration requires
interactions between DL4 and Notch1 (Hozumi et al., 2008; Koch
et al., 2008). Similarly ADAMproteasesmediating S2 cleavage of
Notch receptors are also differentially used between the two cell
lineages. Whereas ADAM 10 is essential for Notch2-dependent
MZ B cell development, loss of ADAM 10 or ADAM17 function
results only in a partial block in T cell development (Gibb et al.,
2010; Li et al., 2007; Tian et al., 2008), thereby pointing to
different requirements for S2 cleavage between the two Notch-
dependent lymphoid lineages. Thus, it is conceivable that Notch
signaling mediated by different Notch components uses a cell-
type-specific genetic program to induce different lymphoid
lineages.
More surprisingly, the requirements for Hes1 function within
a given lineage, which presumably uses the same Notch
signaling components, appear to differ. The competitive BM
chimera studies combined with the IT transfer experiments
show that Hes1-deficient progenitors have a clear disadvantage
to generate thymocytes compared toWT cells. Nevertheless, we
did not observe the accumulation of immature B or myeloid cells
in thymi of Hes1 mutant mice, which is unlike Notch1 or DL4
mutant mice (Feyerabend et al., 2009; Hozumi et al., 2008;
Koch et al., 2008; Radtke et al., 1999). Thus, in the absence of
Hes1, thymus-seeding progenitors are able to integrate enough
of a Notch1-induced genetic program to repress development
and/or accumulation of immature B cells. However, this genetic
program is suboptimal for efficient T cell development, which
results in severe thymic hypoplasia under steady state and
competitive conditions. Exposure of Hes1-deficient progenitors
to a suboptimal ligand such as DL1 results in the development of
immature B cells, whereas WT progenitors retain the ability to
make T cells (Besseyrias et al., 2007). Overall, we demonstrate
that Hes1 is a major component of Notch1-induced signaling
during T cell lineage commitment.
Interestingly, once the T cell lineage has been specified,
thymocyte maturation was not measurably perturbed in the
absence of Hes1. This result is surprising given that Notch
signaling in DN thymocytes assures proliferation and survival
and cooperates with pre-TCR signaling to allow a successful
progression of DN thymocytes to the DP stage (Ciofani et al.,I2006; Ciofani et al., 2004; Ciofani and Zu´n˜iga-Pflu¨cker, 2005;
Maillard et al., 2006; Wolfer et al., 2002). Thus, the requirement
for Hes1 during T cell maturation differs and is less stringent
than its requirement during T cell lineage specification.
The consequences of Hes1 inactivation in adult BM progeni-
tors appear to be different from FL cells (Tomita et al., 1999).
Adoptive transfer experiments of Hes1/ FL cells showed that
T cell development was arrested at the DN stage. Only transplan-
tation of high numbers of FL cells allowed for progression to the
DN3 stage, although these FL-derived Hes1/ cells did not
undergo TCR rearrangement. In contrast toHes1DMxCreBMcells,
Hes1/ FL cells did not further develop to DP or CD4+ SP and
CD8+SP thymocytes. Thus, it was concluded that Hes1 is neces-
sary for successful expansion of thymocyte progenitors and TCR
rearrangement (Tomita et al., 1999). On the contrary, in FTOC
Hes1/ progenitors developed into T cells albeit with a low
frequency (Kaneta et al., 2000). This is similar to our observations
with Hes1DMxCre BM chimeras. The reason for the different out-
comes between in vivo and in vitro analysis of Hes1 FL progeni-
tors is currently unclear. The discrepancy of the in vivo T cell
phenotypes may reflect the consequence of the cell of origin
used (Watanabe et al., 1997). Thus, it is conceivable that Hes1
functionmight be different in FL cells compared to adult BMcells.
Aberrant Notch signaling has been identified as being a major
cause of T-ALL (Aster et al., 2008). In recent years, much effort
has been put into the identification of target genes and signaling
pathways that are regulated by or cooperate with mutant
NOTCH1 alleles. Several laboratories identified multiple candi-
date genes and pathways includingMyc,Hes1, and genes within
the PI3kinase-Akt pathway (Palomero et al., 2006; Palomero
et al., 2007; Weng et al., 2006). Although the important role of
c-Myc for tumor development and NICD-driven growth in
T-ALL was clearly demonstrated (Li et al., 2008; Weng et al.,
2006), the role of Hes1 in this context has not been addressed.
We demonstrated that Hes1 is important for the development
of T-ALL in a mouse model. Constitutive NICD1 expression
and simultaneous inactivation of Hes1 resulted in the transient
appearance of a DP cell population within the BM compartment,
indicating that Hes1-deficient NICD1-expressing cells have an
intrinsic survival defect. An additional argument in favor of this
possibility is the finding that Hes1 seems to be essential for the
maintenance of T-ALL. Ablation of Hes1 in established T-ALL
cells results in the loss of these cells, accompanied by a strong
counter selection for cells having escaped Hes1 inactivation.
How Hes1 mediates this important survival function on a molec-
ular level is currently unclear.
The finding that loss of Hes1 in our model system does not
noticeably regulate the Akt-pathway as has previously been
shown inDrosophila (Palomero et al., 2007) could be due to other
Notch target genes that might compensate for the loss of Hes1
(Chan et al., 2007). However, if this would indeed be the case,
then the dramatic effect of Hes1 deficiency on T-ALL develop-
ment and maintenance must be mediated by other elements of
the leukemogenic program. Interestingly, a recent report sug-
gested that Hes1 is repressing the deubiquitinase CYLD in
human cell lines, thereby providing a link to NF-kB signaling
(Espinosa et al., 2010). The characterization of Hes1 function
on a molecular level in the context of Notch-induced T-ALL
needs further investigation.mmunity 33, 671–684, November 24, 2010 ª2010 Elsevier Inc. 681
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Hes1 Is Critical for T Cell Development and T-ALLThe reduction of Hes1 levels via shHes1 knockdown in
a human T-ALL cell line confers growth retardation and
increased cell death, implying that an important role for Hes1
might not be restricted to T-ALL mouse models but could also
apply to the human disease. In this context, it is interesting to
note that an important role for Hes1 has recently been suggested
in the context of human CML (Nakahara et al., 2010). Future
investigations are needed to identify which, how, and whether
Hes1 might regulate similar pathways or molecules in T-ALL
and CML.
In conclusion, our results demonstrate distinct requirements
for Hes1 function as a mediator of Notch signaling in different
lymphoid lineages. Although Hes1 is dispensable for Notch2-
mediated specification of MZ B cells, it is a critical mediator of
Notch1-induced T cell fate induction. Once the T cell lineage
has been specified, Hes1 function is dispensable for subsequent
thymocyte maturation. In addition, Hes1 plays an important role
for both development and maintenance of Notch1-induced
T-ALL in the mouse. Collectively, our data reveal unexpected
context-dependent heterogeneity in the pathways responsible
for mediating Notch signaling in the hematopoietic system.
EXPERIMENTAL PROCEDURES
Mice
Mice carrying conditional floxed Hes1 alleles (Hes1lox/lox) were generated with
standard gene-targeting techniques. A detailed description can be found in the
Supplemental Information and Figure 1. The generation of MxCre, LckCre,
Cd4Cre, and RosaNIC mice was previously described elsewhere (Ku¨hn
et al., 1995; Lee et al., 2001; Murtaugh et al., 2003; Wolfer et al., 2001).
Conditional Inactivation and Induction of Floxed Alleles
Mice received five intraperitoneal (i.p.) injections of 2 mg/g body weight (BW)
polyI:polyC (pI-pC - Invivogen) at 2 day intervals. Hesl deletion efficiency
was assessed by Southern blot analysis of genomic DNA derived from control
(Hes1lox/lox) and Hes1-deficient (Hes1DMxCre) total BM cells isolated 6–8 weeks
after pI-pC treatment, digested with PstI restriction enzyme, and quantified by
PhosphorImager analysis. Efficiency of induction of RosaNICDlox/+ MxCre
occurs at >90%. The 550 bp Hes1 probe was generated by PCR amplification
from a genomic DNA template with the following primers: forward
50-CACGTGCTCCGACTCCAGGCGCGCCCT-30; reverse 50-CTCTAATGT
CTTCCGGAATTCCC-30.
Retroviral vectors
The coding sequence of the intracellular domain of themurine Notch1 receptor
lacking the PEST domain (corresponding to amino acids 1751–2443) was
created by PCR amplification from the murine Notch1 cDNA template. The
sequence was flanked by EcoRI restriction sites (underlined) by amplification
with the following primer pair: forward 50-CCGGAATTCGCCACCATGG
ATCCGCGGCGCCAG-30; reverse 50-CGGGAATTCCTACAGTGATGTTGGT
AGGGCTG-30. The modified NICD1 construct was cloned into the EcoRI site
of the Migr1 vector, a pMSCV2.2-based retroviral vector containing an
IRES-eGFP cassette (Pui et al., 1999).
Retroviral Production and BM Infection
Retrovirus (RV) was produced by transient calcium phosphate-based cotrans-
fection of Bosc23 cells with emptyMigr1 vector, or Migr1-NICD1, and the pCL-
ECO packaging vector (Imgenex). RV supernatants were collected at 48 and
72 hr. Five days prior to BM isolation, donor animals received a single i.p. injec-
tion of 5-FU (150 mg/kg BW). BM samples were enriched for Lin cells with
a lineage cell depletion kit and AutoMACS separator (Miltenyi Biotec).
Enriched Lin BM progenitor cells were plated at 1 to 2 3 106 cells/well in
a 24-well tissue culture plate in Iscove’s medium containing 20% FBS,
25 mMHEPES, 55 mM 2ME, 2mM glutamine, 0.1 m nonessential amino acids,682 Immunity 33, 671–684, November 24, 2010 ª2010 Elsevier Inc.1 mM sodium pyruvate, 100 ng/ml Flt-3L, 10 ng/ml IL-1, 6 ng/ml IL-3, 10 ng
IL-7, and 100 ng/ml SCF. Cells were cultured for 48 hr prior to retroviral infec-
tion. Transduction of BM progenitors was performed by spinoculation in RV
supernatant containing 4 mg polybrene. Transduced cells were transplanted
intravenous (i.v.) into sublethally irradiated CD45.1+ recipients (2 3 105 cells
per recipient).
BM Transplantation and PBL Preparation
BM chimeras were generated by i.v. injection of 2.5 to 5 3 106 CD45.2+ BM
cells into lethally irradiated (900 cGy) CD45.1+ recipients, pretreated with
anti NK1.1 mAb (Pk1.36). Control or Hes1-deficient BM was transplanted
6–8 weeks after the last pI-pC injection. Mixed BM chimeras were generated
by cotransplanting i.v. a mixture of 1 3 106 CD45.1+ and 3 3 106 CD45.2+
BM cells of the appropriate genotype into CD45.1+ recipients. Total BM
(53 106 cells) from either control or Hes1DMxCremixed BM chimeras was seri-
ally transplanted 12 weeks after generation of the primary chimeras into
secondary lethally irradiated CD45.1+ recipient mice. Peripheral blood
lymphocyte (PBL) screening for donor cell reconstitution was performed 6–
8 weeks after BM transplantation.
Intrathymic Injection
Control, Hes1DMxCre or CD45.1:CD45.2 double congenic lineage-depleted BM
cells (CD45.2+) were injected at 1 3 106 cells per lobe into the thymi of suble-
thally irradiated (550 cGy) congenic recipient mice (CD45.1+). Analysis of
thymic populations was performed by FACS analysis 9–21 days after IT
injection.
Flow Cytometry, Cell Purification, and Cell Sorting
The methods were performed as previously described (Koch et al., 2008).
A detailed list of mAbs used for analysis and experimental modifications are
provided in the Supplemental Information.
OP9 Cell Coculture System
The OP9-DL1 and -DL4 coculture systemwas previously described elsewhere
(Besseyrias et al., 2007).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
immuni.2010.11.014.
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